Aberrant mesolimbic dopamine-opiate interaction in obesity

NeuroImage

Volumn 122, Issue , 2015, Pages 80-86

  Tuominen, Lauri ^a,b   Tuulari, Jetro ^a   Karlsson, Henry ^a   Hirvonen, Jussi ^a   Helin, Semi ^a   Salminen, Paulina ^c   Parkkola, Riitta ^c   Hietala, Jarmo ^a,b   Nuutila, Pirjo ^a   Nummenmaa, Lauri ^a,d  

^a TURKU PET CENTRE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d AALTO UNIVERSITY   (Finland)

Author keywords

Dopamine; Interaction; Obesity; Opioid; PET

Indexed keywords

CARBON 11; CARFENTANIL C 11; DOPAMINE; DOPAMINE 2 RECEPTOR; MU OPIATE RECEPTOR; RACLOPRIDE C 11; UNCLASSIFIED DRUG; CARFENTANIL; DRD2 PROTEIN, HUMAN; FENTANYL; RACLOPRIDE;

ADULT; ARTICLE; BODY MASS; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; LIMBIC SYSTEM; MOLECULAR INTERACTION; MORBID OBESITY; NERVE CELL NETWORK; NEUROIMAGING; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; VENTRAL STRIATUM; VENTRAL TEGMENTUM; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; PUTAMEN; REWARD; SCINTISCANNING;

ADULT; BODY MASS INDEX; CAUDATE NUCLEUS; FEMALE; FENTANYL; HUMANS; MIDDLE AGED; OBESITY; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID, MU; REWARD; VENTRAL STRIATUM;

EID: 84939611724     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2015.08.001     Document Type: Article

References (49)

1. Alakurtti K., Aalto S., Johansson J.J., Någren K., Tuokkola T., Oikonen V., Laine M., Rinne J.O. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J. Cereb. Blood Flow Metab. 2011, 31:155-165.
2. Ambrose L.M., Unterwald E.M., Van Bockstaele E.J. Ultrastructural evidence for co-localization of dopamine D2 and micro-opioid receptors in the rat dorsolateral striatum. Anat. Rec. A: Discov. Mol. Cell. Evol. Biol. 2004, 279:583-591.
3. Andersen P.H. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur. J. Pharmacol. 1988, 146:113-120.
4. Atalayer D., Pantazatos S.P., Gibson C.D., McOuatt H., Puma L., Astbury N.M., Geliebter A. Sexually dimorphic functional connectivity in response to high vs. low energy-dense food cues in obese humans: an fMRI study. Neuroimage 2014, 100:405-413.
5. Azaryan A.V., Clock B.J., Cox B.M. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem. Res. 1996, 21:1411-1415.
6. Balodis I.M., Kober H., Worhunsky P.D., White M.A., Stevens M.C., Pearlson G.D., Sinha R., Grilo C.M., Potenza M.N. Monetary reward processing in obese individuals with and without binge eating disorder. Biol. Psychiatry 2013, 73:877-886.
7. Bencherif B., Guarda A.S., Colantuoni C., Ravert H.T., Dannals R.F., Frost J.J. Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J. Nucl. Med. 2005, 46:1349-1351.
8. Bettinardi V., Presotto L., Rapisarda E., Picchio M., Gianolli L., Gilardi M.C. Physical performance of the new hybrid PET/CT Discovery-690. Med. Phys. 2011, 38:5394-5411.
9. Brady K.T., Randall C.L. Gender differences in substance use disorders. Psychiatr. Clin. North Am. 1999, 22:241-252.
10. Brent P.J., Bunn S.J. In vivo treatment with mu and delta, but not kappa-selective opioid agonists reduces [3H]spiperone binding to the guinea-pig striatum: autoradiographic evidence. Brain Res. 1994, 654:191-199.
11. Brooks S.J., Cedernaes J., Schiöth H.B. Increased prefrontal and parahippocampal activation with reduced dorsolateral prefrontal and insular cortex activation to food images in obesity: a meta-analysis of fMRI studies. PLoS One 2013, 8:e60393.
12. Colasanti A., Searle G.E., Long C.J., Hill S.P., Reiley R.R., Quelch D., Erritzoe D., Tziortzi A.C., Reed L.J., Lingford-Hughes A.R., Waldman A.D., Schruers K.R., Matthews P.M., Gunn R.N., Nutt D.J., Rabiner E.A. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol. Psychiatry 2012, 72:371-377.
13. Cometta-Morini C., Maguire P.A., Loew G.H. Molecular determinants of mu receptor recognition for the fentanyl class of compounds. Mol. Pharmacol. 1992, 41:185-196.
14. Devine D.P., Leone P., Pocock D., Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 1993, 266:1236-1246.
15. Endres C.J., Bencherif B., Hilton J., Madar I., Frost J.J. Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. Nucl. Med. Biol. 2003, 30:177-186.
16. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986, 231:258-261.
17. Frost J.J., Wagner H.N., Dannals R.F., Ravert H.T., Links J.M., Wilson A.A., Burns H.D., Wong D.F., McPherson R.W., Rosenbaum A.E. Imaging opiate receptors in the human brain by positron tomography. J. Comput. Assist. Tomogr. 1985, 9:231-236.
18. García-García I., Horstmann A., Jurado M.A., Garolera M., Chaudhry S.J., Margulies D.S., Villringer A., Neumann J. Reward processing in obesity, substance addiction and non-substance addiction. Obes. Rev. 2014, 15:853-869.
19. Gonzalez-Nicolini M.V., Berglind W., Cole K.S., Keogh C.L., McGinty J.F. Local mu and delta opioid receptors regulate amphetamine-induced behavior and neuropeptide mRNA in the striatum. Neuroscience 2003, 121:387-398.
20. Gorelick D.A., Kim Y.K., Bencherif B., Boyd S.J., Nelson R., Copersino M., Endres C.J., Dannals R.F., Frost J.J. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol. Psychiatry 2005, 57:1573-1582.
21. Greenway F.L., Fujioka K., Plodkowski R.A., Mudaliar S., Guttadauria M., Erickson J., Kim D.D., Dunayevich E., Group C.-I.S. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376:595-605.
22. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997, 6:279-287.
23. Hagelberg N., Kajander J.K., Någren K., Hinkka S., Hietala J., Scheinin H. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. Synapse 2002, 45:25-30.
24. Heinz A., Reimold M., Wrase J., Hermann D., Croissant B., Mundle G., Dohmen B.M., Braus D.F., Braus D.H., Schumann G., Machulla H.J., Bares R., Mann K. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch. Gen. Psychiatry 2005, 62:57-64.
25. Henriksen G., Willoch F. Imaging of opioid receptors in the central nervous system. Brain 2008, 131:1171-1196.
26. Hietala J., West C., Syvälahti E., Någren K., Lehikoinen P., Sonninen P., Ruotsalainen U. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology 1994, 116:285-290.
27. Hirvonen J., Aalto S., Hagelberg N., Maksimow A., Ingman K., Oikonen V., Virkkala J., Nagren K., Scheinin H. Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:275-286.
28. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
29. Jalabert M., Bourdy R., Courtin J., Veinante P., Manzoni O.J., Barrot M., Georges F. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16446-16450.
30. Karlsson H.K., Tuominen L., Tuulari J.J., Hirvonen J., Parkkola R., Helin S., Salminen P., Nuutila P., Nummenmaa L. Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain. J. Neurosci. 2015, 35:3959-3965.
31. Kennedy J., Dimitropoulos A. Influence of feeding state on neurofunctional differences between individuals who are obese and normal weight: a meta-analysis of neuroimaging studies. Appetite 2014, 75:103-109.
32. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
33. Laviolette S.R., Nader K., van der Kooy D. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav. Brain Res. 2002, 129:17-29.
34. Mick I., Myers J., Stokes P.R., Erritzoe D., Colasanti A., Bowden-Jones H., Clark L., Gunn R.N., Rabiner E.A., Searle G.E., Waldman A.D., Parkin M.C., Brailsford A.D., Nutt D.J., Lingford-Hughes A.R. Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. Int. J. Neuropsychopharmacol. 2014, 1-6.
35. Morgane P.J., Galler J.R., Mokler D.J. A review of systems and networks of the limbic forebrain/limbic midbrain. Prog. Neurobiol. 2005, 75:143-160.
36. Moulton E.A., Elman I., Becerra L.R., Goldstein R.Z., Borsook D. The cerebellum and addiction: insights gained from neuroimaging research. Addict. Biol. 2014, 19:317-331.
37. Penttilä J., Kajander J., Aalto S., Hirvonen J., Någren K., Ilonen T., Syvälahti E., Hietala J. Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. Int. J. Neuropsychopharmacol. 2004, 7:431-439.
38. Pollard H., Llorens-Cortes C., Schwartz J.C. Enkephalin receptors on dopaminergic neurones in rat striatum. Nature 1977, 268:745-747.
39. Ray R., Ruparel K., Newberg A., Wileyto E.P., Loughead J.W., Divgi C., Blendy J.A., Logan J., Zubieta J.K., Lerman C. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9268-9273.
40. Salokangas R.K., Vilkman H., Ilonen T., Taiminen T., Bergman J., Haaparanta M., Solin O., Alanen A., Syvälahti E., Hietala J. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am. J. Psychiatry 2000, 157:632-634.
41. Schott B.H., Minuzzi L., Krebs R.M., Elmenhorst D., Lang M., Winz O.H., Seidenbecher C.I., Coenen H.H., Heinze H.J., Zilles K., Düzel E., Bauer A. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J. Neurosci. 2008, 28:14311-14319.
42. Small D.M., Jones-Gotman M., Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 2003, 19:1709-1715.
43. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2046-2050.
44. Tomasi D., Wang G.J., Wang R., Caparelli E.C., Logan J., Volkow N.D. Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors. Hum. Brain Mapp. 2014, 36:120-136.
45. Tuominen L., Nummenmaa L., Keltikangas-Järvinen L., Raitakari O., Hietala J. Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems. Hum. Brain Mapp. 2014, 35:1875-1884.
46. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
47. Volkow N.D., Wang G.J., Fowler J.S., Tomasi D. Addiction circuitry in the human brain. Annu. Rev. Pharmacol. Toxicol. 2012, 52:321-336.
48. Volkow N.D., Wang G.J., Tomasi D., Baler R.D. The addictive dimensionality of obesity. Biol. Psychiatry 2013, 73:811-818.
49. Wiskerke J., Schetters D., van Es I.E., van Mourik Y., den Hollander B.R., Schoffelmeer A.N., Pattij T. μ-Opioid receptors in the nucleus accumbens shell region mediate the effects of amphetamine on inhibitory control but not impulsive choice. J. Neurosci. 2011, 31:262-272.